GlassScriptPhysician profile
Michelle L Collins
NPI 1235235813
$8,923.72
in general payments reported to CMS, 2019-2025
20 companies · $2,988 in 2025
The $2,988 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $1,492 · 2023: $1,501 · 2024: $2,531 · 2025: $2,988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,847 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,846.65 |
| Education | $172.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,590.95 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $894.77 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $890.01 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $704.27 | 2021-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $700.39 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $591.51 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $556.02 | 2022-2025 | Ingrezza |
| Corium, LLC | $504.74 | 2022-2025 | Azstarys |
| Alkermes, INC. | $473.36 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $432.15 | 2022-2025 | Qelbree, Qelbree |
| Sunovion Pharmaceuticals INC. | $349.08 | 2021-2022 | |
| Lundbeck LLC | $344.03 | 2022-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $317.53 | 2022-2024 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $260.13 | 2024-2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $123.82 | 2025 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $82.30 | 2025 | Erzofri Extended-Release |
| Almatica Pharma LLC | $39.54 | 2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $36.25 | 2021-2022 | |
| Indivior INC. | $16.59 | 2024 | Perseris |
| Noven Therapeutics, LLC | $16.28 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.